Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gary Larson

Showing results (1-10 of 30) with videos related to

Pageof 3
Sort By:
Medical Physics|June 10, 2016
Minimizing treatment planning errors in proton therapy using failure mode and effects analysisYuanshui Zheng, Randall Johnson, Gary Larson
Antimicrobial Agents and Chemotherapy|September 25, 2004
Dual-action mechanism of viramidine functioning as a prodrug and as a catabolic inhibitor for ribavirinJim Zhen Wu, Gary Larson, Zhi Hong
Journal of Computational Biology : a Journal of Computational Molecular Cell Biology|February 14, 2020
Incorporating Nearest-Neighbor Site Dependence into Protein Evolution ModelsGary Larson, Jeffrey L Thorne, Scott Schmidler
Journal of Medical Physics|December 20, 2014
Dosimetric impact of number of treatment fields in uniform scanning proton therapy planning of lung cancerSuresh Rana, Hilarie Simpson, Gary Larson, et al.
Journal of Virology|June 20, 2002
Selection of 3'-template bases and initiating nucleotides by hepatitis C virus NS5B RNA-dependent RNA polymeraseJae Hoon Shim, Gary Larson, Jim Zhen Wu, et al.
Antimicrobial Agents and Chemotherapy|May 27, 2005
Phosphorylation of ribavirin and viramidine by adenosine kinase and cytosolic 5'-nucleotidase II: Implications for ribavirin metabolism in erythrocytesJim Zhen Wu, Gary Larson, Heli Walker, et al.
Bioorganic & Medicinal Chemistry Letters|January 30, 2007
Structure-activity relationship (SAR) studies of quinoxalines as novel HCV NS5B RNA-dependent RNA polymerase inhibitorsFrank Rong, Suetying Chow, Shunqi Yan, et al.
Molecular Cancer Therapeutics|September 21, 2006
2-Methoxyestradiol suppresses microtubule dynamics and arrests mitosis without depolymerizing microtubulesKathy Kamath, Tatiana Okouneva, Gary Larson, et al.
Bioorganic & Medicinal Chemistry Letters|October 13, 2006
Identification of novel, selective and potent Chk2 inhibitorsGary Larson, Shunqi Yan, Huanming Chen, et al.
Molecular Cancer Therapeutics|March 17, 2007
Biochemical and cellular characterization of VRX0466617, a novel and selective inhibitor for the checkpoint kinase Chk2Luigi Carlessi, Giacomo Buscemi, Gary Larson, et al.
Pageof 3

Showing results (1-10 of 30) with videos related to

Sort By:
Pageof 3
Medical Physics|June 10, 2016
Minimizing treatment planning errors in proton therapy using failure mode and effects analysisYuanshui Zheng, Randall Johnson, Gary Larson
Antimicrobial Agents and Chemotherapy|September 25, 2004
Dual-action mechanism of viramidine functioning as a prodrug and as a catabolic inhibitor for ribavirinJim Zhen Wu, Gary Larson, Zhi Hong
Journal of Computational Biology : a Journal of Computational Molecular Cell Biology|February 14, 2020
Incorporating Nearest-Neighbor Site Dependence into Protein Evolution ModelsGary Larson, Jeffrey L Thorne, Scott Schmidler
Journal of Medical Physics|December 20, 2014
Dosimetric impact of number of treatment fields in uniform scanning proton therapy planning of lung cancerSuresh Rana, Hilarie Simpson, Gary Larson, et al.
Journal of Virology|June 20, 2002
Selection of 3'-template bases and initiating nucleotides by hepatitis C virus NS5B RNA-dependent RNA polymeraseJae Hoon Shim, Gary Larson, Jim Zhen Wu, et al.
Antimicrobial Agents and Chemotherapy|May 27, 2005
Phosphorylation of ribavirin and viramidine by adenosine kinase and cytosolic 5'-nucleotidase II: Implications for ribavirin metabolism in erythrocytesJim Zhen Wu, Gary Larson, Heli Walker, et al.
Bioorganic & Medicinal Chemistry Letters|January 30, 2007
Structure-activity relationship (SAR) studies of quinoxalines as novel HCV NS5B RNA-dependent RNA polymerase inhibitorsFrank Rong, Suetying Chow, Shunqi Yan, et al.
Molecular Cancer Therapeutics|September 21, 2006
2-Methoxyestradiol suppresses microtubule dynamics and arrests mitosis without depolymerizing microtubulesKathy Kamath, Tatiana Okouneva, Gary Larson, et al.
Bioorganic & Medicinal Chemistry Letters|October 13, 2006
Identification of novel, selective and potent Chk2 inhibitorsGary Larson, Shunqi Yan, Huanming Chen, et al.
Molecular Cancer Therapeutics|March 17, 2007
Biochemical and cellular characterization of VRX0466617, a novel and selective inhibitor for the checkpoint kinase Chk2Luigi Carlessi, Giacomo Buscemi, Gary Larson, et al.
Pageof 3